Molecular Partners AG
MLLCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$153.6M
Close$
$2.91
27.4% downside
Current Fair Value
27.4% downsideOvervalued by 27.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $153.60 Million |
|---|---|
| Enterprise Value | $88.95 Million |
| Earnings per Share | $-1.65 |
| Beta | 0.68 |
| Outstanding Shares | 38,787,000 |
Return
| Return on Equity | -94.35% |
|---|---|
| Return on Assets | -72.97% |
| Return on Invested Capital | -85.16% |
Valuation & Multiples
| P/E Ratio | -2.31 |
|---|---|
| PEG | 7.12 |
| Price to Sales | - |
| Price to Book Ratio | 4.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.59 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$-0.43
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.40
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Molecular Partners AG
149 employees
CEO: Patrick Amstutz
Molecular Partners AG is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutic proteins, leveraging its proprietary DARPin® technology. Its pipeline features...